Impact of Low-Level Viraemia on Virological Failure in HIV-1-Infected Patients with Stable Antiretroviral Treatment
- 1 May 2015
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 21 (4) , 345-352
Abstract
Background: Low-level viraemia (LLV) occurs in 20–40% of patients achieving viral suppression with antiretroviral therapy (ART). The risk of virological failure (VF: confirmed HIV RNA >200 copies/ml) in these patients is still a matter of debate. Methods: This is a prospective cohort study in HIV-infected adults attending the HIV clinic of a tertiary care hospital in Spain. Patients with HIV RNA 200 copies/ml (HR 59.6; 95% CI 15.7, 227), ritonavir-boosted protease inhibtor (PI/r)-based dual therapy (HR 10.2; 95% CI 2.1, 49.8) and PI/r monotherapy (HR 7.9; 95% CI 1.4, 43.3) were associated with VF. Persistent LLV, defined as HIV RNA 200 copies/ml was the strongest predictor of VF. Over half of patients with persistent viraemia <200 copies/ml showed VF.Keywords
This publication has 25 references indexed in Scilit:
- Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mLPLOS ONE, 2012
- Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patientsJournal of Antimicrobial Chemotherapy, 2012
- Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2012
- Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line TherapyThe Journal of Infectious Diseases, 2011
- Low-Level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a New RegimenHIV Research & Clinical Practice, 2009
- Resistencias genotípicas en pacientes con VIH-1 y grados de viremia persistentemente bajosEnfermedades Infecciosas y Microbiología Clínica, 2009
- Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcomeJournal of Antimicrobial Chemotherapy, 2008
- Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/mlAIDS, 2006
- Virological rebound after suppression on highly active antiretroviral therapyAIDS, 2003
- Effect of Influenza Vaccination on Viral Replication and Immune Response in Persons Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral TherapyThe Journal of Infectious Diseases, 2000